Scpharmaceuticals Sales General And Administrative To Revenue from 2010 to 2024
| SCPH Stock | USD 3.35 0.11 3.18% |
Sales General And Administrative To Revenue | First Reported 2010-12-31 | Previous Quarter 3.53 | Current Value 3.14 | Quarterly Volatility 0.22069774 |
Check Scpharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scpharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 502.9 K, Interest Expense of 8.5 M or Selling General Administrative of 56 M, as well as many indicators such as Price To Sales Ratio of 14.22, Dividend Yield of 0.0 or PTB Ratio of 6.81. Scpharmaceuticals financial statements analysis is a perfect complement when working with Scpharmaceuticals Valuation or Volatility modules.
Scpharmaceuticals | Sales General And Administrative To Revenue |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out the analysis of Scpharmaceuticals Correlation against competitors. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.741 | Quarterly Revenue Growth 1.641 | Return On Assets (0.42) | Return On Equity (1.67) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.